Citation: | Zhao JF,Hao DF,Li T,et al.Analysis of clinical features and treatment of pyoderma gangrenosum[J].Chin J Burns Wounds,2022,38(6):506-511.DOI: 10.3760/cma.j.cn501225-20220317-00068.Schilf P, Schmitz M, Derenda-Hell A, et al. Inhibition of glucose metabolism abrogates the effector phase of bullous pemphigoid-like epidermolysis bullosa acquisita[J]. J Invest Dermatol, 2021,141(7):1646-1655.e3. DOI: 10.1016/j.jid.2021.01.014. |
[1] |
GoldustM,HagstromEL,RathodD, et al.Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum[J].Expert Rev Clin Pharmacol,2020,13(2):157-161.DOI: 10.1080/17512433.2020.1709825.
|
[2] |
Santa LuciaG, DeMaioA, KarlinS, et al. A case of extracutaneous pyoderma gangrenosum in a patient with persistent cutaneous and systemic symptoms: implications for differential diagnosis and treatment[J].JAAD Case Rep,2021,15:85-87.DOI: 10.1016/j.jdcr.2021.07.019.
|
[3] |
JinSY, ChenM, WangFY, et al. Applying intravenous immunoglobulin and negative-pressure wound therapy to treat refractory pyoderma gangrenosum: a case report[J].Int J Low Extrem Wounds,2021,20(2):158-161.DOI: 10.1177/1534734620940459.
|
[4] |
GeorgeC,DeroideF,RustinM.Pyoderma gangrenosum - a guide to diagnosis and management[J].Clin Med (Lond),2019,19(3):224-228.DOI: 10.7861/clinmedicine.19-3-224.
|
[5] |
SasorSE,SoleimaniT,ChuMW,et al.Pyoderma gangrenosum demographics, treatments, and outcomes: an analysis of 2,273 cases[J].J Wound Care,2018,27(Suppl 1):S4-8.DOI: 10.12968/jowc.2018.27.Sup1.S4.
|
[6] |
PlatzerKD,KostnerL,VujicI,et al.Clinical characteristics and treatment outcomes of 36 pyoderma gangrenosum patients - a retrospective, single institution observation[J].J Eur Acad Dermatol Venereol,2019,33(12):e474-e475.DOI: 10.1111/jdv.15803.
|
[7] |
IlterN,KeskinN,AdisenE,et al.Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma mimicking pyoderma gangrenosum[J].Australas J Dermatol,2021,62(4):e605-e607.DOI: 10.1111/ajd.13708.
|
[8] |
PinardJ, ChiangDY, MostaghimiA, et al. Wounds that would not heal: pyoderma gangrenosum[J].Am J Med,2018,131(4):377-379.DOI: 10.1016/j.amjmed.2017.12.009.
|
[9] |
BordaLJ, WongLL, MarzanoAV, et al.Extracutaneous involvement of pyoderma gangrenosum[J].Arch Dermatol Res,2019,311(6):425-434.DOI: 10.1007/s00403-019-01912-1.
|
[10] |
ZhangXH, JiaoY. Takayasu arteritis with pyoderma gangrenosum: case reports and literature review[J].BMC Rheumatol,2019,3:45.DOI: 10.1186/s41927-019-0098-z.
|
[11] |
ChakiriR,BaybayH,HatimiAE,et al.Clinical and histological patterns and treatment of pyoderma gangrenosum[J].Pan Afr Med J,2020,36:59.DOI: 10.11604/pamj.2020.36.59.12329.
|
[12] |
冯尘尘,杨转花,李高洁,等. 坏疽性脓皮病诊疗研究进展[J]. 中国麻风皮肤病杂志,2022,38(6):414-418. DOI: 10.12144/zgmfskin202206414.
|
[13] |
AbdelmaksoudA.Pyoderma gangrenosum: a clinical conundrum[J]. J Eur Acad Dermatol Venereol,2018,32(10):e381-e382.DOI: 10.1111/jdv.14977.
|
[14] |
KimYJ,YangHJ,LeeMW,et al.Cutaneous indicator of myelodysplastic syndrome: sudden bullous pyoderma gangrenosum[J].Jpn J Clin Oncol,2020,50(8):958-959.DOI: 10.1093/jjco/hyz207.
|
[15] |
傅汝倩, 康志娟, 李志辉. 化脓性关节炎、坏疽性脓皮病和痤疮综合征孪生兄弟报道[J]. 中华实用儿科临床杂志, 2021, 36(5): 382-384. DOI: 10.3760/cma.j.cn101070-20191015-00985.
|
[16] |
Martinez-RiosC, JariwalaMP, HighmoreK, et al. Imaging findings of sterile pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome: differential diagnosis and review of the literature[J].Pediatr Radiol,2019,49(1):23-36.DOI: 10.1007/s00247-018-4246-1.
|
[17] |
FeldmanSR, LacyFA, HuangWW. The safety of treatments used in pyoderma gangrenosum[J]. Expert Opin Drug Saf,2018,17(1):55-61.DOI: 10.1080/14740338.2018.1396316.
|
[18] |
HrinML,BashyamAM,HuangWW,et al.Mycophenolate mofetil as adjunctive therapy to corticosteroids for the treatment of pyoderma gangrenosum: a case series and literature review[J].Int J Dermatol,2021,60(12):e486-e492.DOI: 10.1111/ijd.15539.
|
[19] |
McKenzieF, CashD, GuptaA, et al.Biologic and small molecule medications in the management of pyoderma gangrenosum[J].J Dermatolog Treat,2019,30(3):264-276.DOI: 10.1080/09546634.2018.1506083.
|
[20] |
信跃文,柴艳芬,姚咏明.皮肤调节性T细胞与创面愈合及免疫疾病的关系研究进展[J].中华烧伤杂志,2020,36(2):156-160.DOI: 10.3760/cma.j.issn.1009-2587.2020.02.015.
|
[21] |
HoffmanKP, ShearerS, ChungC, et al.Clinical and therapeutic overlap of pyoderma gangrenosum, cutaneous small vessel vasculitis, and immunoglobulin A[J].Int J Dermatol,2020,59(8):e286-e288. DOI: 10.1111/ijd.14841.
|
[22] |
王克甲,王耘川,计鹏,等.手术治疗坏疽性脓皮病一例[J].中华烧伤杂志,2016,32(3):187-188.DOI: 10.3760/cma.j.issn.1009-2587.2016.03.014.
|
[23] |
OuazzaniA, BertheJV, de FontaineS.Post-surgical pyoderma gangrenosum: a clinical entity[J]. Acta Chir Belg, 2007,107(4):424-428. DOI: 10.1080/00015458.2007.11680088.
|
[24] |
陈宾,李叶扬,梁岷,等.坏疽性脓皮病误诊为皮肤感染性溃疡一例[J].中华烧伤杂志,2015,31(3):230-231.DOI: 10.3760/cma.j.issn.1009-2587.2015.03.020.
|
[25] |
WangJY, FrenchLE, ShearNH, et al.Drug-induced pyoderma gangrenosum: a review[J]. Am J Clin Dermatol,2018,19(1):67-77. DOI: 10.1007/s40257-017-0308-7.
|
[26] |
曾琳茜,姚越,黄欣,等.生物制剂在坏疽性脓皮病治疗中的研究进展[J/OL].中国皮肤性病学杂志,2022(2022-03-17)[2022-04-22]. https://kns.cnki.net/kcms/detail/detail.aspx?doi=10.13735/j.cjdv.1001-7089.202110142. [网络预发表]. https://kns.cnki.net/kcms/detail/detail.aspx?doi=10.13735/j.cjdv.1001-7089.202110142
|
[27] |
SongH,LahoodN,MostaghimiA.Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series[J].Br J Dermatol, 2018, 178(2):363-368.DOI: 10.1111/bjd.15850.
|
[28] |
吴超,晋红中.坏疽性脓皮病的辅助检查及治疗[J].中华临床免疫和变态反应杂志,2019,13(4):301-305.DOI: 10.3969/j.issn.1673-8705.2019.04.010.
|
[29] |
刘崔.坏疽性脓皮病的临床特点及治疗分析[J/CD].临床检验杂志:电子版,2017,6(2):290-291.
|
[30] |
Di GuidaA, FabbrociniG, ScalvenziM, et al.Coexistence of bullous pemphigoid and pyoderma gangrenosum[J].J Clin Aesthet Dermatol,2022,15(1):16-17.
|
[31] |
HaJW, HahmJE, KimKS, et al. A case of pyoderma gangrenosum with myelodysplastic syndrome[J].Ann Dermatol,2018,30(3):392-393.DOI: 10.5021/ad.2018.30.3.392.
|
[32] |
HaagC, HansenT, HajarT, et al. Comparison of three diagnostic frameworks for pyoderma gangrenosum[J].J Invest Dermatol,2021,141(1):59-63.DOI: 10.1016/j.jid.2020.04.019.
|
[33] |
吴超,方凯,晋红中.泼尼松联合依那西普治疗并发坏疽性脓皮病的关节病性银屑病[J].临床皮肤科杂志,2016,45(3):197-199.DOI: 10.16761/j.cnki.1000-4963.2016.03.014.
|
[34] |
BaltazarD, HaagC, GuptaAS, et al.A comprehensive review of local pharmacologic therapy for pyoderma gangrenosum[J].Wounds,2019,31(6):151-157.
|
[35] |
褚万立,郝岱峰,赵景峰,等. 慢性创面外露内置物的保全和创面修复临床策略[J]. 中华烧伤杂志,2020,36(6):484-487. DOI: 10.3760/cma.j.cn501120-20190215-00027.
|
[36] |
QureshiA,PersaudK,ZulfiqarS, et al.Atypical pyoderma gangrenosum: a case of delayed recognition[J].J Community Hosp Intern Med Perspect,2021,11(2):242-248. DOI: 10.1080/20009666.2020.1866250.
|
[37] |
Penalba-TorresM,Zarco-OlivoC,Calleja-AlgarraA.Postsurgical pyoderma gangrenosum: a diagnosis we cannot miss[J].Med Clin (Barc),2021,157(12):597.DOI: 10.1016/j.medcli.2021.02.019.
|
[38] |
高琼,薛晓东.创面床准备的研究进展[J].临床医学研究与实践,2017,2(28):194-196.DOI: 10.19347/j.cnki.2096-1413.201728096.
|
[39] |
吴新果,黄茜,周小勇.糖皮质激素联合环孢素A治疗溃疡型坏疽性脓皮病1例[J].中国皮肤性病学杂志,2015,29(11):1203,1207.DOI: 10.13735/j.cjdv.1001-7089.201411011.
|
[40] |
吴志华,郭红卫.糖皮质激素作用机制进展及在皮肤科中的应用[J].皮肤病与性病,2011,33(6):321-324,339.DOI: 10.3969/j.issn.1002-1310.2011.06.004.
|